A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
Public ClinicalTrials.gov record NCT07200128. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Satisfaction and Treatment Experiences With RitlEcitiNib And Traditional Treatments for Severe Alopecia Areata Among Adults in the United States (SERENATA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a secondary analysis of the Adelphi Real World Alopecia Areata II United States Disease Specific Programmes database. This database contains data from a cross-sectional study capturing linked physician and patient survey data for dermatologists who treat alopecia areata and patients diagnosed with alopecia areata in the United States. The retrospective analysis of these data will evaluate experiences of patients and dermatologists receiving/prescribing ritlecitinib for severe alopecia areata in the United States. Specifically, the study will describe characteristics of patients who received ritlecitinib for severe alopecia areata, including demographics, clinical characteristics at the time of starting ritlecitinib, and their alopecia areata-related treatment history. The study will also report dermatologist satisfaction with treatment and change in the patient's alopecia areata severity and disease activity from the start of ritlecitinib to different time points on treatment.
Study identification
- NCT ID
- NCT07200128
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2, 2025
- Primary completion
- May 29, 2025
- Completion
- May 29, 2025
- Last update posted
- Jun 9, 2026
2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer | New York | New York | 10001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07200128, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07200128 live on ClinicalTrials.gov.